SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Cohance Lifesciences

BSE: 543064 29 Jun 2025
Healthcare
₹ 981.15
SUVEN PHARMACEUTICALS LIMITED specializes in Pharmaceuticals within the Healthcare sector.

Cohance Lifesciences - Share Price & Details

Market Cap
₹36,118
High /Low
1,360 / 789.0
Stock P/E
136.0
Book Value
₹66.6
Dividend Yield
0.0
ROCE
16.8
ROE
₹14.1
Face Value
1.0
PEG Ratio
-42.1
EVEBITDA
₹83.7
Debt
279
CMP / FCF
178.0
Debt to equity
₹0.16
NP Ann
265
High price all time
1,360
Piotroski score
₹4.0
Graham Number
126.0
No. Eq. Shares
38.3
Net CF
₹36.2
Net profit
265
Price to book value
14.2
Interest Coverage
₹28.8
Low price all time
87.0
Industry PE
32.7
Reserves
₹1,671
Free Cash Flow
₹132

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
Cohance Lifesciences LimitedNANANANA36,118136.0
IPCA LABORATORIES LTD.NANANANA3436239.6
AJANTA PHARMA LTD.11885.22252.611704.1183148734.4

Peer Comparison Chart


About Cohance Lifesciences

SUVEN PHARMACEUTICALS LIMITED, with Security Code 543064, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Suven Pharmaceuticals Faces Short-Term Decline Amid Long-Term Growth Resilience

(20 May 2025)
Suven Pharmaceuticals faced a decline on May 20, 2025, underperforming its sector. The stock opened lower and reached an intraday low, indicating a...
Read more →

JSA advises on $3 billion Suven Pharma–Cohance Lifesciences merger

(19 May 2025)
Cohance Lifesciences Limited has merged with and into Suven Pharmaceuticals Limited in a ~$3 billion (combined) merger.
Read more →

Cohance Lifesciences Ltd | Stock Share Price Live

(19 May 2025)
Master Score B : Suven Pharmaceuticals Ltd. is a leading pharmaceutical company specializing in contract development and manufacturing services (CDMO).
Read more →

JSA Advises Advent International and Suven Pharmaceuticals on USD 3 Billion Merger with Cohance Lifesciences

(15 May 2025)
JSA advised Advent International and Suven Pharmaceuticals Limited, which is listed in India, in the ~USD 3 billion dollar (combined)...
Read more →

Suven Pharmaceuticals is now Cohance Lifesciences

(10 May 2025)
The Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from Suven Pharmaceuticals Limited...
Read more →

Suven Pharmaceuticals rebrands as Cohance Lifesciences

(10 May 2025)
Suven Pharmaceuticals Limited, an integrated CDMO(Contract Development and Manufacturing Organization) serving customers across the globe,...
Read more →